La cadena de opciones muestra datos clave de las opciones de acciones de Hoth Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Hoth Therapeutics..

Hoth Therapeutics (NASDAQ:HOTH) Bolsa, Cadena de Opciones

Hoth Therapeutics

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Markets

Trading Ideas

APLD

EAST

HOTH

Qualigen Therapeutics, Inc. - Common Stock

QLGN

SGLY

SIFY

Mercados mixtos en EE.UU. el jueves, con el Nasdaq subiendo un 0,2% y Dow Jones ganando un 0,06%. Sectores de consumo lideran alzas.

Mercados mixtos mientras los subsidios por desempleo de EEUU caen

Hoth Therapeutics Inc

Morgan Stanley analyst Michael Phillips maintains Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) with a Underweight and raises the price target from $15 to $23.

Price Target

Analyst Ratings

LMND

Morgan Stanley Maintains Underweight on Lemonade, Raises Price Target to $23

WIIM

TZUP

Thumzup shares are trading higher after the company announced its board of directors approved Bitcoin as a treasury reserve asset.

EYEN

Eyenovia shares are trading lower after the company announced that its CHAPERONE trial is not meeting its primary endpoint, prompting the discontinuation of the study and a review of the full data set to evaluate next steps for the program.

Morgan Stanley analyst Joseph Moore maintains Applied Mat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) with a Equal-Weight and lowers the price target from $185 to $179.

AMAT

Morgan Stanley Maintains Equal-Weight on Applied Mat, Lowers Price Target to $179

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Buy and maintains $46 price target.

Reiteration

ITOS

HC Wainwright & Co. Reiterates Buy on ITeos Therapeutics, Maintains $46 Price Target

NEWP

New Pacific Metals Announces Filing Of Preliminary Economic Assessment For The Carangas Project

The Arena Group Holdings, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AREN#AMEX">AREN</a>) shares jumped premarket on Friday after the company delivered the first quarter of<a href="https://www.benzinga.com/pressreleases/24/11/b41989682/the-arena-group-generates-4-0-million-in-net-income-for-third-quarter-of-2024-first-ever-profitabl" target="_blank" rel="noreferrer noopener"> positive net income</a>.
Arena, which is home to hundreds of media brands, including TheStreet, Parade Media, Men&#8217;s Journal, Surfer, Powder and Athlon Sports, reported a net income of $4.0 million, or EPS of $0.11, in the third quarter of 2024, compared to a net loss of $11.2 million, or EPS loss of $0.47 per share a year ago quarter.
Adjusted EBITDA stood at $11.2 million compared to $3.1 million a year ago quarter. Revenue from continuing operations came in at $33.6 million, vs. $37.0 million a year ago quarter.
The company reduced quarterly operating expenses by 51% year-over-year, achieving a $13.6 million positive swing in quarterly income from continuing operations. This highlights the rapid effectiveness of its transformation plan.
The Arena Group CEO Sara Silverstein said, &#8220;We&#8217;re achieving meaningful revenue diversification, including a significant increase in e-commerce and other revenue, enabling a substantial improvement in profitability. We generated higher gross margins, returned to positive operating income, and delivered our first-ever quarter of positive net income.&#8221;
Arena&#8217;s affiliate commerce business grew 287% during the six months, driven by strong organic traffic to commerce posts and stronger partnerships with retailers who value its highly transactional audience.
The company expanded its commerce coverage while increasing revenue per post by 57% in the third quarter versus second quarter of 2024.
Arena finalized a deal to license its proprietary content management system, which also included the acquisition of multiple sites, notably the top-tier automotive platform Autoblog.
Additionally, Arena extended the maturity of its credit line with Simplify Inventions, LLC, and converted $15 million of debt into common equity.
Price Action: AREN shares are up 210% at $1.76 premarket at the last check Friday.
Photo via 761409 from Pixabay
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42002487" target="_blank" rel="noreferrer noopener">Mounjaro-Maker Eli Lilly Files Lawsuit Against US Agency Over Drug Rebate Program</a></li>
</ul>

Small Cap

Movers

AREN

Why Is TheStreet Parent Arena Group Stock Rocketing Premarket Friday?

Thumzup Board Approves Purchase Of Up To $1M In Bitcoin

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.12) by 50 percent. The company reported quarterly sales of $35.00 thousand which missed the analyst consensus estimate of $67.50 thousand by 48.15 percent. This is a 23.91 percent decrease over sales of $46.00 thousand the same period last year.

AIM ImmunoTech Q3 2024 GAAP EPS $(0.06) Beats $(0.12) Estimate, Sales $35.00K Miss $67.50K Estimate

FCEL

FuelCell Energy Announces Global Restructuring, Focusing Core Technologies On Distributed Power Generation: Company To Reduce Total Operating Costs By An Estimated 15% In Fiscal Year 2025

Nexxen International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.11 by 27.27 percent. The company reported quarterly sales of $90.200 million which beat the analyst consensus estimate of $87.125 million by 3.53 percent. This is a 12.62 percent increase over sales of $80.094 million the same period last year.

Earnings Beats

NEXN

Nexxen International Q3 2024 Adj. EPS $0.14 Beats $0.11 Estimate, Sales $90.200M Beat $87.125M Estimate

Three Midwest cities are emerging as affordable housing havens, requiring much less than the typical six-figure salary <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39614880/now-owning-a-house-in-us-is-more-challenging-than-ever-as-affordability-drops-to-">needed for homeownership in many U.S. markets</a>. Rockford, Illinois; Akron, Ohio; and Canton, Ohio, have secured spots among Realtor.com's top 20 hottest housing markets, offering median home prices around $250,000 – well below the national median of $424,950.
Don't Miss:
<ul>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes and you only need $100</a>.</li>
<li>This company is giving accredited investors an opportunity to invest in this $2 billion fund, <a href="https://www.benzinga.com/money/ignite-funding">with three decades in business they boast an impressive track record of double-digit returns.</a></li>
</ul>
&#8220;The typical [monthly] mortgage payment, assuming a 10% down payment, would be $1,455 or less in these areas,&#8221; reports Hannah Jones, senior economic research analyst at Realtor.com. &#8220;Including tax and insurance costs, the minimum recommended income to afford this payment is roughly $73,000, about 10% less than the national median household income.&#8221;
Rockford, Illinois, leads the group with a median list price of $242,000, attracting buyers with its proximity to Chicago and Milwaukee. Local real estate agent David Dale Johnson of Berkshire Hathaway HomeServices told Realtor.com that his market has had strong activity. &#8220;Inventory levels are still low in Rockford," he said. "Some areas of the Rockford market still see full price or greater offers.&#8221;
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% – 9% are protected by resilient assets, buffering against losses.</a>
Akron, Ohio – the birthplace of NBA superstar LeBron James – presents an attractive option at $228,000. Homes sell in just 36 days, 22 days faster than the national average. The city&#8217;s appeal extends beyond affordability, according to Gregg Mervis, president of the Akron/Summit Convention &amp; Visitors Bureau. &#8220;Greater Akron is an exceptional location that blends urban excitement with natural beauty.&#8221;
Canton, Ohio, with a median price of $252,000, recently topped the Wall Street Journal/Realtor.com Housing Market Ranking. Local expert Paul Gabrail told Realtor.com there is an investment opportunity in the area. &#8220;In terms of ROI, if you can buy a property for a relatively low price while the nation&#8217;s income goes up, you&#8217;ll probably do better in cities like Canton versus bigger cities in the West,&#8221; he said.
See Also: ‘Beating the market through ethical real estate investing' –<a href="https://www.benzinga.com/money/invest-with-roots"> this platform aims to give tenants equity in the homes they live in while scoring 17.38% average annual returns for investors – here&#8217;s how to join with just $100</a>
These Midwestern markets offer unique advantages beyond price points. Rockford provides free college tuition at Northern Illinois University for qualified residents, while Akron has strong climate resilience with just 1.8% of properties at risk of natural disasters over the next 30 years. Realtor.com noted that Canton's status as the birthplace of the NFL and home to the Pro Football Hall of Fame adds cultural significance to its economic appeal.
The continued strength of these markets, consistently ranking since February 2022, suggests a sustainable trend rather than a temporary shift. Their affordability, quality of life and economic opportunity make them viable alternatives <a href="https://www.benzinga.com/real-estate/24/11/41876775/u-s-homebuyers-are-now-56-on-average-as-younger-generations-struggle-with-wildly-unaffordable-market-housing-expert-warns">for homebuyers priced out of larger metropolitan areas</a>.
Read Next:
<ul>
<li>Unlock the hidden potential of commercial real estate –<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

You Don't Need A $100K Salary To Afford A Mortgage In These 3 Livable Cities – Unsurprisingly, In The Midwest

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Leap Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTX#NASDAQ">LPTX</a>) with a Buy and maintains $5.5 price target.

LPTX

HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $5.5 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and maintains $10 price target.

AFMD

HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target

UBS analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) with a Buy rating and announces Price Target of $21.

Initiation

UBS Initiates Coverage On Telix Pharmaceuticals with Buy Rating, Announces Price Target of $21

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Genelux (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) with a Buy and lowers the price target from $32 to $30.

GNLX

HC Wainwright & Co. Maintains Buy on Genelux, Lowers Price Target to $30

BMO Capital analyst John Kim upgrades Independence Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRT#NYSE">IRT</a>) from Underperform to Market Perform and raises the price target from $19 to $21.

Upgrades

BMO Capital Upgrades Independence Realty Trust to Market Perform, Raises Price Target to $21

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

POOL

Pool Corp shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

Domino's Pizza shares are trading higher after a 13F filing showed that Berkshire Hathaway added a new stake.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is on the move Wednesday after the clinical-stage biopharmaceutical company <a href="https://finance.yahoo.com/news/hoth-therapeutics-partners-lts-therapy-103000382.html">announced a new partnership</a> with LTS Therapy Systems.



This partnership has the two companies working together to accelerate the development of Hoth Therapeutics&rsquo; candidate for Alzheimer&rsquo;s disease. HT-ALZ is currently pre-clinical with data suggesting it can restore cognitive functions and improve quality of life for Alzheimer&rsquo;s patients.



The agreement with LTS Therapy Systems will see it handle the production of the HT-ALZoral film prototype. This will aid Hoth Therapeutics as it seeks a future Investigational New Drug (IND) Application for clinical trials of the drug.



Hoth Therapeutics CEo Robb Knie said the following about this agreement.




&ldquo;Hoth is excited to announce this partnership and the next milestone in our development of HT-ALZ. We are leveraging LTS&rsquo;s expertise to develop and manufacture the oral film prototypes needed for this particular population and leveraging our positive preclinical results to advance our Alzheimer&rsquo;s therapeutic.&rdquo;




<h2>How This Affects HOTH Stock</h2>



New Alzheimer&rsquo;s treatments are a hot topic right now and this has traders taking notice of HOTH stock today. With that comes heavy trading as some 30 million shares change hands. That&rsquo;s well above the company&rsquo;s daily average trading volume of about 98,000 shares.



HOTH stock is down 2.9% as of Wednesday morning after rallying earlier today.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Wednesday! Among that is what has Rivian&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>), CrowdStrike&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) and Cohere&nbsp;in the news today. All of this info is ready to go at the links below!



<h2>More Stock Market News for Wednesday</h2>



<ul><li><a href="https://investorplace.com/2024/07/rivn-stock-alert-rivian-must-face-lawsuit-over-alleged-tesla-trade-secret-theft/">RIVN Stock Alert: Rivian Must Face Lawsuit Over Alleged Tesla Trade Secret Theft</a></li>



<li><a href="https://investorplace.com/2024/07/crowdstrike-outage-alert-crwd-shares-dip-as-crowdstrike-identifies-bug/">CrowdStrike Outage Alert: CRWD Shares Dip as CrowdStrike Identifies Bug</a></li>



<li><a href="https://investorplace.com/2024/07/cohere-layoffs-2024-what-to-know-about-the-latest-ai-job-cuts/">Cohere Layoffs 2024: What to Know About the Latest AI Job Cuts</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">Why Is Hoth Therapeutics (HOTH) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Hoth Therapeutics (HOTH) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into all of the biggest pre-market stock movers on Thursday morning!



Moving stocks this morning are earnings reports, a public debut, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is rocketing more than 211% after announcing a <a href="https://www.globenewswire.com/news-release/2024/07/24/2918366/0/en/Psyence-Biomed-Announces-Export-of-Nature-Derived-Psilocybin-to-Australia-and-Provides-Update-on-Upcoming-Phase-IIb-Trial.html">psilocybin export to Australia</a> and providing a clinical trial update.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares are soaring over 91% after <a href="https://www.nasdaq.com/press-release/tivic-health-expands-intellectual-property-portfolio-2024-07-23">expanding its intellectual property portfolio</a>.</li>



<li>BloomZ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) stock is surging more than 48% <a href="https://www.wboy.com/business/press-releases/accesswire/891946/bloomz-inc-announces-pricing-of-5-38-million-initial-public-offering/">following its recent public debut</a>.</li>



<li>Cero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cero-stock-quote/">CERO</a>) shares are rising over 32% alongside heavy pre-market trading.</li>



<li>Viking Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vktx-stock-quote/">VKTX</a>) stock is increasing more than 17% after <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-reports-second-quarter-2024-financial-results-and-provides-corporate-update-302205767.html">releasing its Q2 earnings report</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares are gaining close to 17% with strong early morning trading today.</li>



<li>Indivior (NASDAQ:<a href="https://investorplace.com/stock-quotes/indv-stock-quote/">INDV</a>) stock is heading over 14% higher on <a href="https://www.marketwatch.com/story/indivior-shares-jump-on-increased-revenue-100m-share-buyback-5cd4e573?mod=newsviewer_click">Q2 revenue growth</a> and a share buyback.</li>



<li>Signing Day Sports (NYSEMKT:<a href="https://investorplace.com/stock-quotes/sgn-stock-quote/">SGN</a>) shares are jumping more than 14% without any clear news this morning.</li>



<li>Davis Commodities (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtck-stock-quote/">DTCK</a>) stock is getting a 14% boost on Thursday morning.</li>



<li>Stellus Capital Investment (NYSE:<a href="https://investorplace.com/stock-quotes/scm-stock-quote/">SCM</a>) shares are up over 12% despite a lack of news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>2U (NASDAQ:<a href="https://investorplace.com/stock-quotes/twou-stock-quote/">TWOU</a>) stock is plummeting more than 68% with a <a href="https://www.nasdaq.com/press-release/2u-takes-strategic-action-significantly-strengthen-balance-sheet-and-position-company">Chapter 11 bankruptcy filing</a>.</li>



<li>Edwards Lifesciences (NYSE:<a href="https://investorplace.com/stock-quotes/ew-stock-quote/">EW</a>) shares are diving over 22% alongside <a href="https://www.nasdaq.com/press-release/edwards-lifesciences-reports-second-quarter-results-2024-07-24">lackluster Q2 results</a>.</li>



<li>Selina Hospitality (NASDAQ:<a href="https://investorplace.com/stock-quotes/slna-stock-quote/">SLNA</a>) stock is tumbling more than 19% following a rally yesterday.</li>



<li>MaxLinear (NASDAQ:<a href="https://investorplace.com/stock-quotes/mxl-stock-quote/">MXL</a>) shares are taking an over 18% beating after <a href="https://finance.yahoo.com/news/maxlinear-inc-announces-second-quarter-200500103.html">releasing its Q2 earnings report</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) stock is sliding more than 17% after a rally yesterday.</li>



<li>IF Bancorp (NASDAQ:<a href="https://investorplace.com/stock-quotes/iroq-stock-quote/">IROQ</a>) shares are falling over 16% despite a lack of news this morning.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is dropping more than 16% <a href="https://investorplace.com/2024/07/what-is-going-on-with-regencell-bioscience-rgc-stock-today/">alongside recent volatility</a>.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) shares are retreating over 15% <a href="https://investorplace.com/2024/07/why-is-hoth-therapeutics-hoth-stock-moving-today/">with recent volatility</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is decreasing more than 14% <a href="https://investorplace.com/2024/07/why-is-nuzee-nuze-stock-up-133-today/">after rallying yesterday</a>.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) shares close out our pre-market stock movers down over 14% <a href="https://investorplace.com/2024/07/why-is-dermata-therapeutics-drma-stock-up-200-today/">following a Wednesday rally</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-25th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Hoth Therapeutics (HOTH – Research Report) today and set a price target of $4.00. ...

Buy Rating Affirmed for Hoth Therapeutics on Strategic Partnerships and Promising Alzheimer's Treatment Advances

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Hoth Therapeutics (HOTH – Research Report), Rewalk R...

Analysts Offer Insights on Healthcare Companies: Hoth Therapeutics (HOTH), Rewalk Robotics (LFWD) and Rani Therapeutics Holdings (RANI)

Hoth Therapeutics stock climbs on promising preclinical results for its Alzheimer's drug

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Hoth Therapeutics (HOTH – Research Report), retaining the price target of $4.00...

Hoth Therapeutics: Advancements in Alzheimer's and Skin Toxicity Therapies Drive Buy Rating

Hoth Therapeutics (HOTH) announced early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the...

Hoth Therapeutics: Treatment 'successfully' stabilized tumor growth in study

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Hoth Therapeutics: Buy Rating Backed by Promising Preclinical Data and Valuation Analysis

AMRN

ANAB

BLMZ

BMRN

CERO

CRWD

DRMA

DTCK

EXEL

EYPT

GLYC

INCY

INDV

IROQ

ITCI

LFWD

MEIP

MNKD

NUZE

RANI

RGLS

RIVN

RVNC

SLNA

SPRO

TIVC

TWOU

VKTX

VSME

Press Releases

Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024

Contracts

Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery

Hoth Therapeutics Expands Clinical Trial for Cancer Patients

Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment

Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic

Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001

Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial

Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ

Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway

Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study

Comments

Hoth Therapeutics

Hoth Therapeutics (HOTH) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL